Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70422 ↗Kurz gefasst
Leitlinie in der Zeitschrift HemaSphere, online erschienen am 23.06.2026. Verfasst von Dennis A Eichenauer und 17 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group University of Cologn…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hodgkin lymphoma (HL) is a B‐cell‐derived malignancy often affecting young adults. Allocation into risk groups is based on staging with positron emission tomography and computed tomography (PET/CT) and the presence or absence of risk factors. Standard treatment for early‐stage favorable classic HL (cHL) consists of two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), followed by 20 Gy involved‐site radiotherapy (IS‐RT). Two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) or a procarbazine‐free eBEACOPP variant plus two cycles of ABVD, followed by 30 Gy IS‐RT in the case of PET/CT positivity and no further treatment in the case of PET/CT negativity after chemotherapy should be considered in patients with early‐stage unfavorable cHL ≤ 60 years. If a less intensive approach is preferred and in individuals > 60 years, four cycles of A(B)VD followed by 30 Gy IS‐RT can be given. In advanced cHL, brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for four (in the case of PET/CT negativity after two cycles) or six cycles (in the case of PET/CT positivity after two cycles), followed by PET/CT‐guided 30 Gy IS‐RT should be considered in patients ≤ 60 years. Six cycles of nivolumab and AVD (N‐AVD) followed by PET/CT‐guided 30 Gy IS‐RT represents a less intensive alternative for younger patients and the preferred approach for patients > 60 years. Patients with cHL recurrence should receive checkpoint inhibitor‐containing salvage treatment followed by high‐dose chemotherapy and autologous stem cell transplantation if eligible. Treatment of nodular lymphocyte‐predominant HL differs from cHL in some situations and may contain an anti‐CD20 antibody. This guideline aims at providing recommendations for diagnosis, staging, treatment, and follow‐up of HL.
Autor:innen und Institutionen
- First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group University of Cologne Cologne Germany.
- Department of Hematology, CHU UCL Namur Université Catholique de Louvain Yvoir Belgium.
- Department of Haematology, Oxford Cancer and Haematology Centre Churchill Hospital Oxford UK.
- Patient Advocate for Lymphoma Coalition to the EHA Donegal Ireland.
- Department of Radiation Oncology University Hospital Münster Münster Germany.
- CHIMOMO Department University of Modena and Reggio Emilia Modena Italy.
ORCID-Profile: Dennis A Eichenauer, Massimo Federico, Alexander Fossa, Carsten Kobe
Zitieren
APA
Eichenauer, D. A., André, M., Borchmann, P., Collins, G. P., Doherty, I., Eich, H. T., Federico, M., Fossa, A., Hartmann, S., Hutchings, M., Illidge, T., Kobe, C., Plattel, W. J., Specht, L., Sureda, A., Zaucha, J. M., Zijlstra, J. M., & Aurer, I. (2026). Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70422
Vancouver
Eichenauer DA, André M, Borchmann P, Collins GP, Doherty I, Eich HT, et al. Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up. HemaSphere. 2026;10(6). doi:10.1002/hem3.70422
BibTeX
@article{Eichenauer2026,
author = {Eichenauer, Dennis A and André, Marc and Borchmann, Peter and Collins, Graham P and Doherty, Ian and Eich, Hans-Theodor and Federico, Massimo and Fossa, Alexander and Hartmann, Sylvia and Hutchings, Martin and Illidge, Timothy and Kobe, Carsten and Plattel, Wouter J and Specht, Lena and Sureda, Anna and Zaucha, Jan M and Zijlstra, Joseé M and Aurer, Igor},
title = {Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70422}
}
EUVIMED